Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics, Inc. is trading at $116.27, up 1.23% on the session. The 50 day average sits at $97.22 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 62, which reads as strong, and MACD is bullish crossover. Volume is above average.

The nearest support is around $106.24 with resistance near $116.47, so that band frames the current range. Average daily movement is roughly $5.82, or about 5.0% of the share price, which is what any stop placement has to allow for. The overall health score of 68 out of 100 combines a trend score of 75, momentum of 88 and a risk score of 28.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.